Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 29, Number 6—June 2023

Research

Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain

Cristina Rodríguez-Grande, Agustín Estévez, Rosalía Palomino-Cabrera, Andrea Molero-Salinas, Daniel Peñas-Utrilla, Marta Herranz, Amadeo Sanz-Pérez, Luis Alcalá, Cristina Veintimilla, Pilar Catalán, Carolina Martínez-Laperche, Roberto Alonso, Patricia Muñoz, Laura Pérez-Lago1Comments to Author , Darío García de Viedma1Comments to Author , and on behalf of the Gregorio Marañón Microbiology-ID COVID 19 Study Group2
Author affiliations: Gregorio Marañón General University Hospital, Madrid, Spain (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, M. Herranz, A. Sanz-Pérez, L. Alcalá, C. Veintimilla, P. Catalán, C. Martínez-Laperche, R. Alonso, P. Muñoz, L. Pérez-Lago, D. García de Viedma); Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, A. Sanz-Pérez, L. Pérez-Lago, D. García de Viedma); Universidad Complutense, Madrid (R. Alonso, P. Muñoz); Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias-CIBERES, Madrid (R. Alonso, P. Muñoz, D. García de Viedma)

Main Article

Table 3

Clinical characteristics of cases without short-term SARS-CoV-2 persistence in a study of early SARS-CoV-2 reinfection involving the same or different genomic lineages, Spain*

Characteristic Value, n = 11
Average age, y (range)
 58.5 (1–94)
Sex
M 4 (36.4)
F
 7 (63.6)
Illness severity
Asymptomatic 2 (18.2)
Mild 4 (36.4)
Intermediate 2 (18.2)
Severe
 2 (18.2)
Care required
Emergency 1 (9.1)
Hospital admission 6 (54.5)
Hospital admission for COVID-19 3 (27.3)
Nosocomial transmission 1 (9.1)
ICU 0
ICU for COVID-19
 0
Underlying conditions
None of interest 3 (27.3)
High blood pressure 6 (54.5)
COPD 2 (18.2)
Asthma 1 (9.1)
Diabetes 0
Ictus 1 (9.1)
Overweight/obesity 6 (54.5)
Heart disease 5 (45.5)
Autoimmune 3 (27.3)
Oncological 2 (18.2)
Chronic kidney disease 2 (18.2)
HIV infection 1 (9.1)
AIDS 0
Pregnant 0
Paxlovid use‡ 1 (9.1)
Remdesivir use 3 (27.3)
Tocilizumab use 1 (9.1)
Dexamethasone use
 4 (36.4)
Death
 1 (9.1)
Vaccines and serology
Complete vaccination schedule 8 (72.7)
Incomplete vaccination schedule 1 (9.1)
Unvaccinated 2 (18.2)
Previous positive serology for SARS-CoV-2 3 (27.3)
Previous negative serology for SARS-CoV-2 2 (18.2)
Serology not available 6 (54.5)

*Values are no. (%) except as indicated. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit. †Illness severity was defined according to the following criteria: mild, general unrest, cough, diarrhea, cephalgia, fever, anosmia, myalgias, rhinorrhea; moderate, previous symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; severe, previously listed symptoms plus bilateral pneumonia or severe respiratory failure. ‡Nirmatrelvir/ritonavir.

Main Article

1This senior authors contributed equally to this article.

2Additional members of the Gregorio Marañón Microbiology-ID COVID-19 Study Group who contributed data are listed at the end of this article.

Page created: April 17, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external